全文获取类型
收费全文 | 3337篇 |
免费 | 268篇 |
国内免费 | 33篇 |
专业分类
耳鼻咽喉 | 18篇 |
儿科学 | 224篇 |
妇产科学 | 78篇 |
基础医学 | 504篇 |
口腔科学 | 186篇 |
临床医学 | 279篇 |
内科学 | 702篇 |
皮肤病学 | 60篇 |
神经病学 | 176篇 |
特种医学 | 212篇 |
外科学 | 363篇 |
综合类 | 61篇 |
一般理论 | 16篇 |
预防医学 | 257篇 |
眼科学 | 70篇 |
药学 | 123篇 |
中国医学 | 4篇 |
肿瘤学 | 305篇 |
出版年
2023年 | 21篇 |
2022年 | 18篇 |
2021年 | 37篇 |
2020年 | 28篇 |
2019年 | 24篇 |
2018年 | 70篇 |
2017年 | 67篇 |
2016年 | 62篇 |
2015年 | 74篇 |
2014年 | 110篇 |
2013年 | 157篇 |
2012年 | 171篇 |
2011年 | 164篇 |
2010年 | 137篇 |
2009年 | 134篇 |
2008年 | 153篇 |
2007年 | 170篇 |
2006年 | 136篇 |
2005年 | 131篇 |
2004年 | 98篇 |
2003年 | 70篇 |
2002年 | 86篇 |
2001年 | 72篇 |
2000年 | 43篇 |
1999年 | 92篇 |
1998年 | 126篇 |
1997年 | 108篇 |
1996年 | 110篇 |
1995年 | 75篇 |
1994年 | 83篇 |
1993年 | 50篇 |
1992年 | 55篇 |
1991年 | 59篇 |
1990年 | 48篇 |
1989年 | 58篇 |
1988年 | 55篇 |
1987年 | 52篇 |
1986年 | 58篇 |
1985年 | 49篇 |
1984年 | 34篇 |
1983年 | 33篇 |
1982年 | 26篇 |
1981年 | 26篇 |
1980年 | 22篇 |
1979年 | 18篇 |
1978年 | 14篇 |
1977年 | 23篇 |
1976年 | 23篇 |
1975年 | 22篇 |
1972年 | 12篇 |
排序方式: 共有3638条查询结果,搜索用时 0 毫秒
1.
Iclea Rocha Gama Euclides Marinho Trindade-Filho Suzana Lima Oliveira Nassib Bezerra Bueno Isabelle Tenório Melo Cyro Rego Cabral-Junior Elenita M. Barros Jaqueline A. Galvão Wanessa S. Pereira Raphaela C. Ferreira Bruna R. Domingos Terezinha da Rocha Ataide 《Metabolic brain disease》2015,30(1):93-98
2.
3.
P Avalos-Peralta† A Herrera† JJ Ríos-Martín‡ AM Pérez-Bernal† D Moreno-Ramírez† F Camacho† 《Journal of the European Academy of Dermatology and Venereology》2006,20(1):79-83
We report the case of a patient with a 13-year history of pemphigus vulgaris (PV) treated with immunosuppressive agents, prednisone and mycophenolate mofetil who had developed lesions of Kaposi's sarcoma (KS) on a sole plaque of PV that had been previously treated with intralesional injections of steroids. The lesions were surgically removed and polymerase chain reaction (PCR) demonstrated human herpesvirus-8 (HHV-8) DNA. There were neither recurrences nor later dissemination of KS following gradual decrease of the immunosuppressive therapy. We suggest that the treatment with intralesional steroids may have influenced the local reactivation of a latent infection of the virus, determining the appearance of this localized KS. 相似文献
4.
5.
6.
J. Duteil FA Rambert AM Pointeau P. Mangiameli and E. Assous 《Fundamental & clinical pharmacology》1991,5(8):695-708
The potential antidepressant effect of flerobuterol (dl-(fluoro-2 phenyl)-1 t-butylamino-2 ethanol), a new drug related to beta-adrenoceptor agonists, was evaluated and compared with imipramine and salbutamol using classical psychopharmacological tests in mice. Like imipramine and salbutamol, flerobuterol (0.5-32 mg kg-1, ip) fully prevented apomorphine (16 mg kg-1, sc)- and partly reversed reserpine- and oxotremorine-induced hypothermia. At higher doses (16-32 mg kg-1), flerobuterol enhanced the toxic effects of yohimbine. Unlike imipramine, flerobuterol and salbutamol did not reduce immobility duration in the behavioural despair test. Salbutamol and flerobuterol decreased locomotor activity. Flerobuterol did not induce mydriasis, did not prevent oxotremorine-induced tremors or salivary and lacrimal gland secretion and did not reduce reserpine-induced palpebral ptosis. Propranolol (8 mg kg-1, ip) but not alpha-methyl-paratyrosine (75 mg kg-1, ip) prevented the flerobuterol-induced antagonism of apomorphine-induced hypothermia. Our results suggest that flerobuterol demonstrates potential antidepressant activity, which could be related to beta-adrenoceptor activation in mice. 相似文献
7.
Hillary R Bogner Mark S Cary Martha L Bruce Charles F Reynolds Benoit Mulsant Thomas Ten Have George S Alexopoulos 《The American journal of geriatric psychiatry》2005,13(10):861-868
OBJECTIVE: The authors described the influence of specific medical conditions on clinical remission and response of major depression (MDD) in a clinical trial evaluating a care-management intervention among older primary-care patients. METHODS: Adults age 60 years and older were randomly selected and screened for depression. Participants were randomly assigned to Usual Care or to an Intervention with a depression care-manager offering algorithm-based care for MDD. In all, 324 adults meeting criteria for MDD were included in these analyses. Remission and response was defined by a score on the Hamilton Rating Scale for Depression <10 and by a decrease from baseline of > or =50%, respectively. Medical comorbidity was ascertained through self-report. Cognitive impairment was defined by a score <24 on the Mini-Mental State Exam (MMSE). RESULTS: In Usual Care, rates of remission were faster in persons who reported atrial fibrillation (AF) than in persons who did not report AF and slower in persons who reported chronic pulmonary disease than in persons who did not report chronic pulmonary disease; rates of response were less stable in persons with MMSE <24 than in those with MMSE > or =24. In the Intervention condition, none of the specific chronic medical conditions were significantly associated with outcomes for MDD. CONCLUSIONS: Because disease-specific findings were observed in persons who received Usual Care but not in persons who received more intensive treatment in the Intervention condition, our results suggest that the association of medical comorbidity and treatment outcomes for MDD may be determined by the intensity of treatment for depression. 相似文献
8.
9.
Benign intracranial hypertension and recombinant growth hormone therapy in Australia and New Zealand
PA Crock JD McKenzie AM Nicoll NJ Howard W Cutfield LK Shield G Byrne 《Acta paediatrica (Oslo, Norway : 1992)》1998,87(4):381-386
Benign intracranial hypertension (BIH) is reported in three children from Australia and one from New Zealand, who were being treated with recombinant human growth hormone (rhGH). Three males and one female, aged between 10.5 and 14.2 y, developed intracranial hypertension within 2 weeks to 3 months of starting treatment. A national database, OZGROW, has been prospectively collecting data on all 3332 children treated with rhGH in Australia and New Zealand from January 1986 to 1996. The incidence of BIH in children treated with growth hormone (GH) is small, 1.2 per 1000 cases overall, but appears to be greater with biochemical GHD (<10IUml -1 ), i.e. 6.5/1000 (3 in 465 cases), relative risk 18.4, 95% confidence interval 1.9-176.1, than in all other children on the database. The incidence in patients with Turner's syndrome was 2.3/1000 (1 in 428 cases). No cases in patients with partial GHD (10–20 IUml -1 ) or chronic renal failure were identified. Possible causative mechanisms are discussed. The authors'practice is now to start GH replacement at less than the usual recommended dose of 14IUm-2 week-1 in those children considered to be at high risk of developing BIH. Ophthalmological evaluation is recommended for children before and during the first few months following commencement of rhGH therapy and is mandatory in the event of peripheral or facial oedema, persistent headaches, vomiting or visual symptoms. The absence of papilledema does not exclude the diagnosis. 相似文献
10.